Silent in one assay, potent in another: VHHs unlock a new way to block the cancer resistance target CDK2 Joint case study profiles VHHs against CDK2/CycE1 in functional biochemical assays and finds binders acting through two distinct mechanisms. CAMBRIDGE, UK and...
Cerberus Therapeutics Enters into Antibody Discovery Agreement with Isogenica to Advance Immune-Modulating Therapies Cambridge, UK – June 17, 2025 — Isogenica Ltd., The VHH Company™, today announced an antibody discovery agreement with Cerberus Therapeutics to support...
From Hit to Clinic: Isogenica and Charles River Collaborate to Accelerate Next-Generation Peptide and VHH Discovery Cambridge, UK – June 4th, 2025 – Every breakthrough begins with discovery. Isogenica, a leader in synthetic VHH antibody and peptide discovery, has...
Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics [Cambridge, UK] – Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of...
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions Cambridge, UK and Milan, Italy, September 26th, 2024. Axxam S.p.A. and Isogenica Ltd. have announced a partnership to bring together functional bioassay...
Isogenica is proud to announce two new Non-Executive Directors Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team. Paul and Trevor will play a crucial role in providing independent oversight,...
